On March 31,BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that it has reached an agreement with a partner for the overseas commercialization of three independently developed drugs—infliximab, trastuzumab, and pertuzumab—in the Turkish market. This marks another critical milestone in BioRay's global expansion strategy and represents a new achievement in the company's overseas market development.

Infliximab and trastuzumab have already received approval in China for treating autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, psoriasis, etc.) and tumors (breast cancer, stomach cancer). Pertuzumab, when used in combination with trastuzumab, can significantly enhance the anti-tumor effect, and its marketing application was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China in October 2024.

Since launching its overseas business in 2022, BioRay has actively expanded its international presence, establishing partnerships in over 30 countries and regions. To date, the company's products have been approved for marketing in three overseas markets, and six successful overseas GMP audits have been completed, laying a solid foundation for global commercialization. Moving forward, BioRay remains committed to innovation-driven growth, accelerating its globalization efforts to deliver high-quality treatment options to patients worldwide.

Dr. Wang Haibin, CEO of BioRay, commented: " drug globalization represents a critical step in our global strategy. As a key emerging market along the 'Belt and Road' initiative, Turkey boasts substantial unmet medical needs. We are confident that by leveraging the strong local capabilities and BioRay’s innovative capabilities, these three products will achieve success in Turkey, delivering more treatment options to patients."